{
    "nct_id": "NCT04635995",
    "official_title": "An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 Agonist Antibody) as a Single Agent, in Combination With LVGN3616 (Anti-PD-1 Antibody), and in Combination With LVGN3616 and LVGN6051 (CD137 Agonist Antibody) in Patients With Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy",
    "inclusion_criteria": "* Males or females aged ≥ 18 years.\n* Ability to understand and willingness to sign a written informed consent document.\n* Patients must have a histologically or cytologically confirmed metastatic or unresectable malignancy.\n* Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.\n* Adequate bone marrow, liver, and renal functions\n* Men and women of childbearing potential must agree to take highly effective contraceptive methods.\n* Patients should recover from all reversible AEs of previous anticancer therapies to baseline.\n* Patients infected with the HIV virus will be eligible if the disease is under control of effective therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with anti-CD40 therapy.\n* Receipt of systemic anticancer therapy or radiotherapy within certain period of time.\n* Prior exposure to immune-therapeutics experienced Grade ≥ 3 drug-related toxicity, or a toxicity requiring discontinuation.\n* Received a live-virus vaccine within 30 days of the first dose of study drug.\n* Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.\n* History of Grade ≥ 3 immune-related AEs (irAEs).\n* Prolonged QT syndrome, or clinically significant cardiac condition.\n* Receiving an immunologically based treatment for any reason.\n* History or current active or chronic autoimmune disease.\n* Uncontrolled pleural effusion, pericardial effusion, or recurrent ascites drainage.\n* Female patients who are pregnant or breastfeeding.\n* History of hemorrhagic or ischemic stroke within the last 6 months.\n* Previously received an allogeneic tissue/organ transplant, stem cell or bone marrow transplant or solid organ transplant.",
    "miscellaneous_criteria": ""
}